ABIVAX
Clinical-stage biotech developing therapeutics for chronic inflammatory diseases.
ABVX | PA
Overview
Corporate Details
- ISIN(s):
- FR0012333284 (+1 more)
- LEI:
- 969500D8TMNB184OJU95
- Country:
- France
- Address:
- 7 BOULEVARD HAUSSMANN, 75009 PARIS
- Website:
- https://www.abivax.com
- Sector:
- Manufacturing
Description
Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2018-04-27 00:00 |
DDR 27042018 10h30
|
French | DOCX • 6.9 MB | ||
| 2018-04-27 00:00 |
signature DDR
|
French | PDF • 163.9 KB | ||
| 2018-04-27 00:00 |
Lettre fin travaux PWC DDR 2017
|
French | PDF • 708.3 KB | ||
| 2018-04-27 00:00 |
Lettre fin travaux PWC DDR 2017
|
French | PDF • 1.3 MB | ||
| 2018-04-27 00:00 |
DDR 27042018
|
French | DOCX • 6.9 MB | ||
| 2018-04-26 00:00 |
DDR 26042018
|
French | DOCX • 6.9 MB | ||
| 2018-04-20 18:00 |
Information relative au nombre total de droits de vote et d'actions composant l…
|
French | PDF • 256.1 KB | ||
| 2018-04-20 00:00 |
DDR 20042018
|
French | DOCX • 5.2 MB | ||
| 2018-04-17 00:00 |
HONORAIRES AUDIT
|
French | PDF • 13.4 KB | ||
| 2018-04-16 15:03 |
• Informations Sociétales Rapport du Commissaire aux comptes désigné organisme …
|
French | PDF • 2.0 MB | ||
| 2018-04-16 00:00 |
Rapport d’audit des commissaires aux comptes sur les comptes sociaux d’ABIVAX é…
|
French | PDF • 694.2 KB | ||
| 2018-04-16 00:00 |
rapport spéciaux
|
French | PDF • 708.1 KB | ||
| 2018-04-09 08:00 |
ABIVAX verstarkt sein Management-Team mit der Ernennung von Alexandra Pearce, P…
|
German | HTML • 10.1 KB | ||
| 2018-04-09 08:00 |
Communicated under the obligation to provide permanent information / Other comm…
|
English | PDF • 268.0 KB | ||
| 2018-04-09 08:00 |
Communiqués au titre de l'obligation d'information permanente / Autres communiq…
|
French | PDF • 272.9 KB |
Automate Your Workflow. Get a real-time feed of all ABIVAX filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ABIVAX
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ABIVAX via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-11 | N/A | Other | Buy | 319,107 | N/A |
| 2024-03-01 | N/A | Other | Buy | 7,000 | 91,557.90 EUR |
| 2023-12-19 | N/A | Other | Sell | 50,000 | 482,500.00 EUR |
| 2023-12-11 | N/A | Other | Sell | 2,062 | 19,382.80 EUR |
| 2023-11-13 | N/A | Other | Buy | 4 | 39.84 EUR |
| 2023-07-13 | N/A | Other | Sell | 192,781 | 3,101,480.01 EUR |
| 2023-03-27 | N/A | Other | Other | 38,461 | 249,996.50 EUR |
| 2023-02-27 | N/A | Other | Other | 1,535,000 | 9,977,500.00 EUR |
Peer Companies
